Insightful Science to acquire Dotmatics
Global life sciences software developer Insightful Science plans to acquire cloud-based scientific data management firm Dotmatics of the U.K. Read More
Asher Bio launches to develop cis-targeting immunotherapies
Asher Biotherapeutics has launched after raising $55 million in financing. The company is pioneering a new approach to immunotherapy, called cis-targeting, which seeks to selectively activate immune cell types to drive immune responses. Read More
Selexis, Tallac to advance novel immunotherapies
Selexis and Tallac Therapeutics have signed both a commercial license agreement and service agreement to advance Tallac's toll-like receptor agonist antibody conjugate (TRAAC) platform. Read More
GVN adds Sanofi Pasteur as partner against viral threats
The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence Coalition, an initiative that brings together pharmaceutical company expertise to lead the war against viruses. Read More
Lyell completes $65M cell therapy manufacturing facility
Lyell Immunopharma has completed its $65 million Lyfe Manufacturing Center in Bothell, WA. The facility will be used to produce cell products for upcoming clinical trials. Read More
Aura raises $80M to advance virus-like drug conjugate therapies
Aura Biosciences has closed $80 million in financing to advance the clinical development of its virus-like drug conjugate technology program, including a pivotal phase III program for AU-011, its lead candidate for first-line treatment of choroidal melanoma. Read More
BioRestorative issued 3 patents for stem cell platform
BioRestorative Therapies has been issued three separate patents related to the company's metabolic ThermoStem stem cell program. Read More
Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for targets that are difficult to address with conventional approaches. Read More
AstraZeneca closer to U.S. regulatory submission with interim results
AstraZeneca's COVID-19 vaccine candidate has demonstrated a vaccine efficacy rate of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization in a U.S. phase III clinical trial. Read More
Standards nonprofit launches online portal
The Standards Coordinating Body has launched an online portal to provide access to published standards and to those in development. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
